AI Verdict
LIANY has stronger fundamentals based on our AI analysis.
LIMNW vs LIANY Fundamental Comparison
| Metric | LIMNW | LIANY |
|---|---|---|
| Revenue | N/A | $7.9M |
| Net Income | $-10.2M | $-69.7M |
| Net Margin | N/A | -886.0% |
| ROE | N/A | -34.4% |
| ROA | -1,990.4% | -26.5% |
| Current Ratio | 0.05x | 10.06x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-0.43 | $-0.65 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LIMNW vs LIANY: Frequently Asked Questions
Is LIMNW or LIANY a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LIANY has stronger fundamentals. LIMNW is rated STRONG SELL (95% confidence) while LIANY is rated SELL (72% confidence). This is not investment advice.
How does LIMNW compare to LIANY fundamentally?
Liminatus Pharma, Inc. has ROE of N/A vs LianBio's -34.4%. Net margins are N/A vs -886.0% respectively.
Which stock pays higher dividends, LIMNW or LIANY?
LIMNW has a dividend yield of N/A or no dividend while LIANY has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LIMNW or LIANY for long term?
For long-term investing, consider that LIMNW has STRONG SELL rating with 95% confidence, while LIANY has SELL rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LIMNW vs LIANY?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LIMNW vs LIANY, the AI consensus favors LIANY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.